Skip to main content

Table 1 Association of RBM5, EGFR, and KRAS proteins with clinicopathological characteristics in 120 pair NSCLC specimens

From: Differential Expression of RBM5, EGFR and KRAS mRNA and protein in non-small cell lung cancer tissues

  Total no. of Patients (%) RBM5 EGFR    KRAS
  Low(N) % P High(N) % P High(N) % P
Characteristic           
Gender n
Male 73(61) 56 76.7 0.46 23 31.5 0.597 34 46.6 0.666
Female 47(39) 28 66.7   18 38.3   20 42.6  
Age (years)
Less than 60 37(31) 26 70.3 0.996 12 32.4 0.586 16 43.2 0.796
Greaterthanorequalto60 83(69) 58 69.7   29 34.9   38 45.8  
Smoking status
Former or Current 84(70) 66 78.6 0.001** 14 38.9 0.475 45 53.6 0.002**
Never 36(30) 18 50   27 32.1   8 22.2  
Histology, n
Adenocarcinoma 47(39) 36 76.6 0.206 19 40.4 0.246 17 36.2 0.119
Squamous cell 73(61) 48 65.8   22 30.1   37 50.7  
Lymph node Metastasis
Positive 60(50 %) 50 83 0.008** 27 45 0.009** 34 56.7 0.01*
Negative 60(50 %) 34 56.7   14 23.3   20 33.3  
Tumor TNM stage
IA 16(13 %) 9 56 0.029** 3 18.7 0.031 2 12.5 0.022*
IB 18(15 %) 11 61   5 27.7   5 27.8  
IIA 28(23 %) 17 60.7   6 35.2   7 25  
IIB 23(19 %) 17 73.9   10 43.5   10 43.5  
IIIA 20(17 %) 17 85   9 45   11 55  
IIIB 15(13 %) 13 86.6   8 53.3   9 60  
  1. (Low) reduced expression patients.(High) increased expression patients. Values represent asymptotic two-tailed significance with asterisks denoting *P < 0.05 and **P < 0.01, from the Pearson’s Chi-squared test.